Schiller ties up with CIRCASSIA for `NIOX VERO’ device

Schiller Healthcare has partnered with CIRCASSIA Inc. to introduce FeNO testing device for enhancing patient outcomes.

“Exciting news! Our partnership with CIRCASSIA Inc. brings you NIOX VERO – a revolutionary FeNO testing device that healthcare professionals worldwide trust to enhance patient outcomes. We can’t wait to see the impact it will have on your practice,” SCHILLER India wrote on Linkedin.

Circassia’s NIOX® products are used to improve asthma patient outcomes, and are indicated in the U.S. for use in those aged 7 years and older. NIOX® technology is based on the discovery that patients with Type 2 airway inflammation (previously known as allergic or eosinophilic inflammation), generally have elevated levels of nitric oxide in their exhaled breath. Corticosteroid therapy has been proven to reduce FeNO levels. Research has shown that up to 84% of asthma patients have Type 2 airway inflammation, which is particularly associated with exacerbations. By measuring the concentration of FeNO, NIOX® enables clinicians to evaluate airway inflammation in asthma patients, aiding diagnosis and helping guide treatment to reduce exacerbations.
MB Bureau